Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Hirsch Y, Zeevi DA, Lam BL, Scher SY, Bringer R, Cherki B, et al. A founder deletion in the TRPM1 gene associated with congenital stationary night blindness and myopia is highly prevalent in Ashkenazi Jews. Hum Genome Var. 2019;6:45.

Jin C, Huang Y, Nasim M, Yang Y, Lee L. Gastrointestinal Stromal Tumors Risk Stratification Utilizing Phospho-Histone H3 Evaluated by Manual Counting and Computer-Assisted Image Analysis. Int J Surg Pathol. 2019;27(7):706-712.

Baum JE, Soong L, Scognamiglio T, Margolskee EM, Hoda RS, Rao R. Cytological diagnosis of papillary thyroid carcinoma with tall cells on ThinPrep liquid-based cytology. Diagn Cytopathol. 2019;47(6):541-546.

Sun L, Thorson T, Zhu R, Huo J, Tong J, Rodgers WH, et al. A case report of parotid mammary analogue secretory carcinoma and reviews. Int J Surg Case Rep. 2019;55:88-91.

Cao C, Oswald AB, Fabella BA, Ren Y, Rodriguiz R, Trainor G, et al. The Ca1.2 L-type calcium channel regulates bone homeostasis in the middle and inner ear. Bone. 2019;125:160-168.

Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173.

Li F, Deng Z, Zhang L, Wu C, Jin Y, Hwang I, et al. ATRX loss induces telomere dysfunction and necessitates induction of alternative lengthening of telomeres during human cell immortalization. EMBO J. 2019;38(19):e96659.

Nissim S, Leshchiner I, Mancias JD, Greenblatt MB, Maertens O, Cassa CA, et al. Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer. Nat Genet. 2019;51(9):1308-1314.

Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, et al. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019;60(12):2917-2921.

Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.